Limbal Stem Cell Therapy by Kringlegarden, Hilde Grane
Obligatorisk oppgave 
Det medisinske embetsstudium 






















Morten C. Moe 









	   2	  
ABSTRACT  
 
It is widely accepted today that stem cells in the adult corneal epithelium is located to the 
limbus. No specific marker of limbal epithelial cells (LESCs) has been identified, yet many 
have been suggested, including ΔNp63α, ABCG2, vimentin and notch 1. Negative markers 
include amongst others the differentiation markers Ck3 and Ck12. The lack of an identified 
specific marker elucidates the need for establishment of more exact molecular markers of 
LESCs. 
Limbal stem cell deficiency (LSCD) may result from a variety of aetiologies, such as 
chemical and thermal injuries, and represents an important cause of loss of vision and 
blindness worldwide. There is an ongoing discussion about the definition of this condition and 
a diagnosis with clear criteria has not been established for LSCD. The treatment options vary 
depending on the presentation of the LSCD. In partial LSCD when the central cornea and the 
visual axis are not affected, conservative management is indicated. If there is involvement of 
the central cornea in partial LSCD, surgical management is indicated, including mechanical 
debridement of conjunctival epithelium from the corneal surface and/or amniotic membrane 
transplantation. When total LSCD is present, surgical management with replacement of the 
damaged or absent limbal stem cells is currently the treatment of choice. The transplants can 
either be large whole tissue limbal epithelial grafts, or ex vivo expanded limbal epithelial 
grafts from small biopsies of limbal epithelium. The expanded limbal epithelial cells can be 
autologous or allogenic.  
Ex vivo expansion of limbal epithelial cells in culture is a relatively new technique for 
the treatment of LSCD, and no international or national guidance has been established. This 
has resulted in several studies seeking to investigate this technique, but these studies are hard 
to compare due to different variables, such as methods of ex vivo expansion, allo- versus 
autografts, composition of the culture medium, the surgical management, postoperative 
management, and the definition of a successful outcome. 
The composition of the culture medium is essential for the culture of limbal epithelial 
cells, and fetal calf serum, various hormones and growth factors have been included in most 
studies. Concern has been raised about the use of animal-derived products in the culture 
systems where LESCs are expanded, as this implies a possibility for interspecies pathogen 
transfer when transplanting the grafts, including prion diseases. This risk is further augmented 
due to the fact that immunosuppression is required. In the past years, researches have 
investigated options trying to exclude animal-derived products.  
So far, transplantation of these grafts has shown promising results as a way of treating 
LSCD with an overall success rate of 76 %. Although this number is based on studies with a 
wide range of differences, the success rates seem to be fairly consistent, but long-term follow-
up is needed. More research in this field is required to improve the established, but not yet 
standardised, techniques. Ideally an international guidance should be established for a culture 
method free of non-human derived products, and which is also governed by the principles of 
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ABBREVIATIONS 
BCVA: Best corrected visual acuity 
FSP:  Focal stromal projection 
HLEC: Human limbal epithelial cells 
LC:  Limbal crypt 
LEC:  Limbal epithelial crypt 
LESC:  Limbal epithelial stem cell 
LSCD:  Limbal stem cell deficiency 
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1. INTRODUCTION AND METHOD 
 
The transparent cornea enables the transmission of light to the retina for normal vision. The 
cornea is located in the anterior part of the eye, where it borders the conjunctiva. The 
transition zone is termed the limbus, and it is thought to contain stem cells, termed limbal 
epithelial stem cells. Corneal epithelial cells are constantly lost from the corneal surface to the 
tear film, and the corneal surface is continuously renewed by the limbal epithelial stem cells. 
Limbal stem cell deficiency is a condition that occurs upon significant injury to the limbal 
epithelium, and may be the result of a variety of causes. The condition is characterized by 
visual impairment and pain. Limbal stem cell therapy, specifically ex vivo expansion of 
limbal epithelial cells and transplantation of limbal epithelial explants, is a relatively new 
technique and treatment option for limbal stem cell deficiency. The aim of this literature study 
is to summarize and review the published literature concerning limbal epithelial stem cells, 
limbal stem cell deficiency and limbal stem cell therapy.  
 The literature included was gathered from anatomy books and by searching the 
databases McMaster Plus and PubMed, as well as the search engine Primo. Literature 
included was collected with guidance from Professor Morten C. Moe. The following phrases 
were used when searching the databases: “limbal stem cells”, “limbal epithelial stem cells”, 
“limbal epithelial stem cell markers”, “limbal stem cell deficiency”, “ex vivo expansion of 
limbal epithelial cells”.  
 
2. ANATOMY AND TERMS  
2.1 The bulbus oculi  
The bulbus oculi, or the eyeball, is situated in the anterior part of the orbit. The bulbus oculi 
has a diameter of approximately 2.5 cm and is globe-shaped, except for the anterior part, 
where it bulges outward. This outward projection represents approximately one-sixth of the 
total area of the bulbus oculi and is the transparent cornea  (1,2). The cornea borders the 
conjunctiva, and the transition zone is termed the limbus.  
 
2.2 The cornea and the limbus  
The cornea consists of five layers. The first layer is the outer surface covered by the corneal 
epithelium, which is a stratified squamous non-keratinizing epithelium. The corneal 
epithelium continues into the conjunctival epithelium at the edges of the cornea, called the 
limbus. The next layer is the Bowman’s layer; the outer, acellular zone of the stroma. The 
third layer is the corneal stroma. This layer constitutes about 80 % of the corneal thickness 
and consists of densely packed yet transparent connective tissue. The transparency is thought 
to originate from the corneal stroma’s regularly ordered and equally spaced collagen bundles, 
produced by the corneal fibrocytes called keratocytes. The fourth layer is the Descemet’s 
membrane, which is the thick basement membrane of the innermost layer, the endothelium. 
The endothelium separates the cornea from the aqueous humor of the anterior chamber of the 
eye, provides the stromal keratocytes with nutrients and participates in the maintenance of 
stromal transparency via its transport functions. In the limbal area, the stroma continues into 
the sclera, while the endothelium is connected through a transition zone with the trabecular 
meshwork, continuing into the anterior surface of the iris and the suprachoroidal space. The 
limbus is an approximately 2 mm broad and 1 mm thick ring of tissue inserted between the 
cornea and the conjunctiva (1).  
 At the limbal zone, which is the transition between the cornea and the conjunctiva, the 
corneal structure changes (3). The epithelium thickens and forms epithelial pegs made up of 
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10-12 cell layers instead of five layers as in the central cornea. The Bowman’s layer is 
missing and the undulated epithelial basement membrane lies directly above the limbal 
stroma, in which the collagen bundles become less organized and cells are abundant and 
fibroblast like. These unique structures of the limbal surface are called ”limbal palisades of 
Vogt”, and they are radially oriented. The Descemet’s membrane is also missing in the 
limbus, and the epithelial cells of the transition zone (transitional cells) are larger and flatter 




Figure 1 (3). Localization of corneal stem cells. A: Histological section and tissue layers of 
the cornea. B: The corneal limbus is localized to the corneoscleral border. The upper and 
lower regions most protected by the eyelids contain the Vogt’s palisades that apparently host 
most of the corneal epithelial stem cells. C: Cross-section of the corneoscleral transition. The 
corneal epithelium is contiguous with the conjunctiva, the corneal stroma transits into the 
sclera, whereas the corneal endothelium is linked with the trabecular meshwork. These 
transitional zones together contain the majority of stem cells in the adult cornea.  
 
2.3 Stem cells 
Stem cells are characterized by several properties (3): 
a. asymmetric self-renewal, meaning that during cell division, the stem cell gives rise to 
daughter cells with different properties – one copy of the stem cell and one cell that 
will differentiate into tissue-specific cells 
b. undifferentiated state, but with high differentiation potential – implying the ability to 
differentiate into all cell types of their home tissue and possibly into other cell types as 
well, when appropriate (experimental) circumstances are provided  
c. slow cell cycle, that is, most of the time, stem cells are in a growth arrested state, 
however, they can enter cell cycle on demand (e.g., tissue injury), and give rise to a 
differentiating and highly proliferative progeny (progenitor cells) 
d. requirement for a stem cell niche – stem cells usually reside in a microenvironment 
that provides external factors necessary for maintaining stem cell properties and 
functions, often referred to as ”stemness”  
 
There are adult/somatic stem cells and embryonic stem cells. Embryonic stem cells are 
pluripotent and therefore can become all cell types of the body, except for extraembryonic 
tissue cells, while adult stem cells only can differentiate into the cell types of their tissue of 
origin. Adult stem cell populations are found in most adult tissues and are able to maintain 
and regenerate the given tissue for a lifetime. Embryonic stem cells grow fast, while adult 
stem cells grow slow.  
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Progenitor cells are similar to stem cells in most aspects regarding b, except they do 
not renew themselves indefinitely and their population becomes terminally differentiated after 
a limited, though sometimes enormous number of cell divisions (3). Their cell cycle is fast.     
 
3. LIMBAL EPITHELIAL STEM CELLS 
 
3.1 Localisation of limbal epithelial stem cells 
It is widely accepted today that the stem cells in the adult corneal epithelium is located to the 
limbus. Davanger and Evensen first proposed this in 1971 (4), when they observed pigmented 
epithelial migration lines moving from the limbal area towards the central cornea during 
healing process, hence indicating that the limbal area could be the reservoir of the new 
epithelial cells (3). Cell movement was later observed centripetally from the corneoscleral 
limbus during wound healing (5). Since then, there have been several experimental and 
clinical studies supporting this hypothesis of corneal stem cells located	  to	  the	  limbus	  (3).	  	  
Cotsarelis provided the second evidence of limbal epithelial stem cells (LESCs) when 
detecting label-retaining cells in the basal layer of the limbal epithelium in 1989 (6). 
Following pulse labelling of replicating DNA, Cotsarelis found that these limbal cells contain 
an easily detectable amount of label in their nucleus in comparison to frequently dividing 
cells, where the amount of label quickly is reduced. Consecutive studies confirmed this 
finding (3). 	  
We differentiate between three clonal types of human epithelial cells, as clonogenic 
keratinocytes can generate holoclones, meroclones and paraclones, which have different 
capacities for multiplication (7). The holoclone-forming cell is the smallest colony-founding 
keratinocyte, generates all the epithelial lineages of the tissue of origin and has self-renewal 
ability, telomerase activity and an impressive proliferative capacity. The progression of clonal 
type follows holoclone à meroclone à paraclone, the two latter having properties expected 
of transient amplifying progenitors because they have limited proliferative capacity. 
Meroclones have an intermediate proliferative potential and they are a reservoir of paraclones. 
Holoclones are the only one possessing indefinite regenerative properties. Holoclones 
represent only approximately 1-5 % of clonogenic keratinocytes, the vast majority of which 
generate meroclones and paraclones (7). Cell culture studies have shown that cells from the 
central cornea generated mostly paraclones, i.e. terminated colonies which could not be 
passaged more than twice, whereas cells from the limbal area could proliferate for many 
generations (80-100 doublings) and form large holoclone colonies. The peripheral corneal 
cells formed meroclone colonies whose growth was stopped after a relatively small number of 
divisions - these cells are also referred to as transient amplifying cells (TACs) (8,9,10). 
We know from animal experiments that surgical removal of the limbus has resulted in 
insufficient re-epithelization and conjunctival invasion of the corneal surface (11). Clinical 
studies have documented that limbal transplantation makes possible long-term restoration of 
the corneal surface in patients with limbal damage (12,13). Also, most epithelial tumours of 
the ocular surface originate from the limbal area. As stem cells in general are considered to be 
the origin of most tumours, this is indicative of a limbal localisation of stem cells 
(14,15,16,17,18).  
The LESCs are thought to reside in the basal layer of the limbal epithelium in 
structures known as the palisades of Vogt and are interspersed with early transient amplifying 
cells (TACs) (3,9).  
In 2008, Majo et al. challenged the dominating opinion that corneal stem cells are 
located only to the corneal limbus. Their study suggests that corneal stem cells are distributed 
throughout the entire mammalian ocular surface. Furthermore, they suggest oligopotence of 
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the corneal stem cells as the cells had capacity to generate goblet cells, which is the hallmark 
of the conjunctiva (19).  
 
3.2 Molecular markers of limbal epithelial stem cells 
As of today, there is not identified any specific marker of LESCs, but many have been 
suggested. Suggested molecular markers used to identify the basal cell layer of the limbal 
epithelium or clusters of cells within it, are thought to identify LESCs together with early 
TACs. Negative markers are differentiation markers that are not present in LESCs. When 
trying to identify LESCs today, one uses a combination of suggested positive and negative 
markers (3).  
One of the most reliable positive LESC markers of today is ΔNp63α. The gene 
products of the p63 gene are transcription factors that are necessary for epithelial 
development and morphogenesis. The p63 gene produces full length (TAp63) and N-
terminally truncated (ΔNp63) transcripts, each of which have α, β, and γ isoforms (3,20). As 
reviewed by Takács L et al in 2009 (3), p63 was shown to identify basal cells with high 
proliferative potential in the skin (21). High p63 content was later observed in limbal 
epithelial cells with high nuclear/cytoplasmic ratio, and p63 was then suggested as an LESC 
marker (10). One also learned that antibodies detecting all isoforms of p63 identified some 
differentiated cells as well (22). Later, the isoform ΔNp63α was shown to more specifically 
identify epithelial stem cells, whereas the β and γ isoforms have been shown to promote 
epithelial cell differentiation (23,24). ΔNp63α is expressed at high levels in holoclones, at 
low levels in meroclones, and is undetectable in paraclones – so the transition from holoclone 
to paraclone is accompanied by the progressive disappearance of ΔNp63α and the relative 
enrichment of ΔNp63β and ΔNp63γ (10,24). Interestingly, the clinical success of engrafted 
limbal cultures was highly correlated to the percentage of stem cells detected as p63bright 
holoclones (25).  
 Another leading candidate as a LESC marker is the ATP-binding cassette transporter 
G2 (ABCG2). As reviewed by Takács L et al., LESCs yield a stem cell rich side population 
(SP) when sorted after incubation with the Hoechst33342 dye, just as hematopoietic, skin and 
muscle cells do (26,27,28). SP phenotype has been attributed to the function of the 
BCRP/ABCG2 transporter protein (29,30,31,32). ABCG2 is an effective Hoechst efflux 
pump. Low fluorescence after staining with Hoechst33342 dye hence indicates the presence 
of ABCG2. ABCG2 was suggested as a LESC marker because cells from limbal explants 
expressing ABCG2 showed high clonogenic potential and expressed high levels of ΔNp63α, 
similarly to side population cells (33). In histological sections, ABCG2 antibodies label small 
clusters of cells in the basal limbal epithelium, and approximately 10 % of the limbal 
epithelial cells are stained. Only about 3 % of the cells appear ABCG2 positive when 
measured by flow cytometry after isolation of single limbal epithelial cells by dispase II-
trypsin digestion of corneas (33). Both of these numbers are higher than the proportion of 
LESCs, which is estimated to be less than 1 % based on the fraction of the side population. 
This may be explained by cytoplasmic (non-functional) expression of ABCG2 in some limbal 
epithelial cells, indicating that ABCG2 labelling with antibodies possibly marks some 
transient amplifying cells as well as LESCs (34).  
 In 2007, Barbaro et al. showed that C/EBPδ (CCAAT-enhancer-binding-protein), 
together with Bmi-1 (B lymphoma Mo-MLV insertion region 1) and ΔNp63α identifies 
mitotically quiescent limbal stem cells, which generate holoclones in culture (35).  
 Other suggested positive markers include vimentin (36), notch 1 (37), and cytokeratins 
14 and 19 (36). 
 Negative markers of LESCs include, amongst others, the cytokeratines Ck3 and Ck12 
(36). They are both differentiation markers of keratinocytes.  
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3.3 The limbal epithelial stem cell niche 
The microenvironment, in the midst of which the stem cells are located, contributes to the 
development and maintenance of the various unique features that characterise a stem cell. The 
niche keep the stem cells undifferentiated and prevent them from turning into TACs. This 
microenvironment is made up of extracellular matrix components, fibroblasts, other resident 
cells, vasculature and the products and signals they release. Collectively they constitute the 
stem cell niche (38). A stem cell niche is also supposed to be a site where structural 
characteristics afford stem cell protection. Today, neither stem cells nor a specific niche for 
stem cells have been identified at the limbus, which is in part related to the lack of a specific 
stem cell marker. The lack of a specific stem cell marker so renders the investigation of the 
limbal stem cell niche difficult.  
 Niche structures are located in the limbal palisades of Vogt, which are radially 
oriented stromal ridges intersected with epithelial rete pegs, observable over the superior and 
the inferior limbus, and missing temporally and nasally (3) The epithelium at the palisades of 
Vogt is enriched in stem cells, as targeted biopsies of limbal regions rich in palisades yield 
higher number of clonogenic LESCs in culture (39).  
 The task of protecting the stem cells is carried out by three attributes of the palisades 
of Vogt: they are situated in those parts of the cornea that are most protected by the eyelids; 
they contain melanocytes that safeguard stem cells from the UV radiation by the transfer of 
melanin granules; and protection from mechanical shear forces is provided at the bottom of 
the rete pegs (3). The palisade ridge regions contain blood vessels that can provide nutrients 
and other supportive factors for the stem cells.  
There have been identified three different structures within the palisades of Vogt that 
contain high numbers of putative stem cells, and so these structures have been considered as 
putative stem cell niches. One of these structures is termed limbal epithelial crypt (LEC). 
LECs extend from the peripheral aspect of the undersurface of an interpalisade rete ridge and 
extend either radially into the conjunctival stroma parallel to the palisade or circumferentially 
along the limbus at right angles to the palisade. The structure is widest at its origin from the 
rete ridge and gradually narrows in direction of its termination (38). LECs contain high 
numbers of epithelial cells expressing the putative LESC markers ABCG2, p63, cytokeratins 
14 and 19, and vimentin, have a high nucleus to cytoplasm ratio and are connected to the 
underlying basement membrane via cytoplasmatic projections (3).  
As reviewed by Takács L et al. (3), the two other structures identified as putative stem 
cell niches are termed limbal crypts (LCs), similar to LECs but also including surrounding 
stroma as opposed to LECs, and focal stromal projections (FSPs). LCs are circumscribed 
downward projections of the limbal epithelium that open to the corneal surface and are in 
close association with the limbal vasculature. FSPs are finger like projections of stroma 
containing a central blood vessel that are surrounded by small, tightly packed epithelial cells. 
The highest numbers of p63α and ABCG2 positive epithelial cells, suspected as stem cells, 
were observed in the basal epithelial layers of LCs and FSPs (39).  
There is little knowledge about the molecular mechanisms controlling limbal niche 
functions today, but cytokines and the interaction of cells with extracellular matrix 
components have been suggested to play an important role in the niche regulation (3).  
 
3.4 Function of the limbal epithelial stem cells 
Corneal epithelial cells are continuously lost from the corneal surface to the tear film, and 
thus the layer must be continuously renewed to ensure a transparent cornea. This is performed 
by the LESCs. The corneal epithelium is renewed approximately every 9-12 months (40). The 
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LESCs also function as a barrier separating the corneal epithelial cells from the conjunctival 
epithelial cells, preventing the conjunctival cells from migrating into the cornea (41).  
 
4. LIMBAL STEM CELL DEFICIENCY  
 
4.1 Definition  
Limbal stem cell deficiency (LSCD) is a condition that occurs upon significant injury to the 
limbal epithelium and the LESCs contained therein. When this happens, the corneal 
epithelium cannot renew itself and as a result, the conjunctival epithelial cells are able to 
expand into the cornea. This process is called “conjunctivalization”. The cornea will no 
longer be transparent, as the process leads to persistent epithelial defects and 
neovascularization of the cornea. Chronic inflammation, scarring and loss of vision will 
ensue. This is an important cause of loss of vision and blindness worldwide (41). LSCD is 
estimated to affect about 10 million individuals worldwide. Of note, there is an ongoing 
discussion about the definition of LSCD and which criteria that should be used.  
 
4.2 Etiology 
LSCD can be primary, related to an insufficient stromal microenvironment to support stem 
cell function, such as aniridia, ectodermal dysplasia, congenital erythrokeratodermia, keratitis 
associated with endocrine deficiencies, neurotrophic (neural and ischaemic) keratopathy and 
chronic limbitis. The LSCD can also be secondary, which is more common, related to 
external factors that destroy LESCs such as chemical (most common) or thermal injuries, 
Stevens-Johnson syndrome, ocular cicatricial pemphigoid, multiple surgeries or 
cryotherapies, long-term contact lens wear, or extensive microbial infections (42,43).  
 
4.3 Clinical assessment of patients with LSCD 
 
4.3.1 Clinical features and symptoms 
Patients report symptoms including visual impairment, ocular discomfort or pain, 
photophobia and tearing. The LSCD may be total or partial, unilateral or bilateral. The 
biomicroscopic findings at slitlamp examination may include a dull and irregular reflex of the 
corneal epithelium, which varies in thickness and transparency. In the case of severe 
malfunction of LESCs, there may be ingrowth of a thickened fibrovascular pannus, chronic 
keratitis, scarring and calcification. Corneal surfaces that are conjunctivalised are often 
stained abnormally by fluorescein as a result of the fact that conjunctival epithelium is more 
permeable than corneal epithelium. In partial LSCD, a clear line of demarcation is often, but 
not always, visible between the corneal and conjunctival phenotype cells. In patients with 
LSCD, persistent epithelial defects, melting and perforation of the cornea may occur.  
 
Clinical features of total LSCD:  
i. Significant epithelial defect 
ii. Significant peripheral and central corneal vascularization 
iii. Marked corneal opacity 
iv. Total loss of Palisades of Vogt 
 
4.3.2 Corneal impression cytology 
Corneal impression cytology remains the most practical way to confirm the diagnosis of 
LSCD. The test is also useful in cases of unilateral LSCD as a way of looking for subclinical 
LSCD in the presumed other healthy eye or to predict culture failure (44). Cultures that 
contain inadequate numbers of LESCs are associated with poor clinical outcome following 
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transplantation (25). Of note, in 2010, Rama et al. reported significant post-procedure pain 
due to epithelial defects and they stopped using impression cytology in their study. They 
considered it to add too little to the clinical assessment to justify the use. To perform 
impression cytology one uses a nitrocellulose filter paper and gently presses it against the 
cornea under topical anesthesia to remove the most superficial cells. These cells are then 
examined to look for evidence of conjunctival epithelium in the cornea. Today, one primarily 
looks at the cytokeratin profile of the cells, as cytokeratin 3 and 12 are present in normal 
corneal cells, whereas cytokeratin 19 is expressed by conjunctival epithelium. This profile 
seems to correlate well with the clinical findings and can confirm or refute the diagnosis of 
LSCD (45). The technique has one important limitation; if an inadequate number of cells are 
removed, the results may be unreliable. 
 
4.3.3 Confocal microscopy  
Confocal microscopy can assist in establishing the clinical diagnosis of LSCD, and can be 
useful to assess outcomes of surgery at a cellular level without the need to remove any tissue. 
It is a technique in which the light source and the condensing lens of the microscope are 
focused on the same point. Live tissue is viewed parallel instead of perpendicular to its 
surface and thus it has high resolution with minimal interference from superficial or deeper 
layers. No actual tissue is removed, although most confocal microscopes require a contact 
technique. Confocal microscopy allows one to look at individual cells and the different 
histological layers and cell types can be identified. Thereby one may distinguish a corneal 
from a conjunctival phenotype. The study of Shortt et al. in 2008 is one of the few studies 
reporting using this technique (44). 
When looking at the cells by confocal microscopy (44), normal corneal epithelial cells 
appear well defined and regular, with bright borders and dark cytoplasm. The cells in the 
superficial layers are flatter and have bright nuclei. They can be clearly differentiated from 
conjunctival epithelial cells, which are hyper-reflective and ill defined (64). In addition, 
conjunctival tissue contains goblet cells and blood vessels, which also can be seen using this 
technique. 
 
4.4 Traditional treatment of LSCD 
One distinguishes between partial and total LSCD. Partial LSCD is when there are still some 
functioning LESCs present, whereas total LSCD is when there is no evidence of functioning 
LESCs left. The distinguishing is important regarding treatment options. If there are no 
significant symptoms and the central cornea, and thereby the visual axis, is not affected in 
partial LSCD, conservative management is indicated. However, in partial LSCD, if there is 
involvement of the central cornea with impaired vision and significant irritation, as well as 
persistent epithelial defect, surgical management is indicated. The management includes 
mechanical debridement of conjunctival epithelium from the corneal surface and/or amniotic 
membrane transplantation. Mechanical debridement with scraping of the cornea is done with 
a surgical blade under topical anaesthesia at the slitlamp. Re-scraping may be done if any 
tendency of conjunctival epithelium to re-encroach the corneal surface occurs (43). Surgical 
management is the only treatment option in total LSCD, involving a stem cell therapy 
replacing the damaged or absent LESCs.  
The conservative management of LSCD includes intensive non-preserved lubrication, 
bandage contact lenses, and autologous serum eye drops. Only the latter is supported by 
evidence in the literature, reviewed by Shortt et al in 2007 (46). In the case of partial LSCD, it 
has been demonstrated that repeated debridement of migrating conjunctival epithelium in the 
acute phase following injury, called sequential conjunctival epitheliectomy (SSCE), can 
reduce or prevent conjunctival ingrowth. Another method is transplantation of an amniotic 
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membrane as an inlay to promote corneal epithelial migration into the area of the LSCD. This 
has been reported successful in partial LSCD.  
Historically, in the case of extensive LSCD, the management was central corneal 
transplantation, but the long-term success was not impressive. This was due to a lack of a 
healthy recipient limbus, with the following inability to maintain the transplanted corneal 
epithelium. In total LSCD, there are no functioning LESCs left, and it is essential to restore a 
functional limbus by transplantation. The transplants can either be large whole tissue limbal 
epithelial grafts, or ex vivo expanded limbal epithelial grafts from small biopsies of limbal 
epithelium. Previously used techniques of transplanting LESCs without ex vivo expansion 
include keratolimbal lamellar allografts, conjunctival-limbal autografts and living-related 
conjunctival-limbal allografts (46). With ex vivo expansion, the biopsies can either be taken 
from the other healthy eye of the patient (autograft) if the LSCD is unilateral and total or from 
a healthy part of the limbus in the ipsilateral eye (autograft) in the case of partial and/or 
bilateral LSCD. In the case of total and bilateral LSCD, the biopsy can be taken from a living 
relative or from a cadaveric donor (allograft). There are two major advantages in using ex 
vivo expanded autografts; only a small amount of tissue is required, and thereby the LESC 
population of the donor eye is less likely to be damaged. The second advantage is that the 
donor tissue is autologous and thereby no systemic immunosuppression is required.  
 
5. EX VIVO EXPANSION AND TRANSPLANTATION OF LIMBAL EPITHELIAL 
EXPLANTS 
 
5.1 Ex vivo expansion of limbal epithelial cells 
 
5.1.1 Historical summary  
Pellegrini and co-workers were the first to describe ex vivo expansion of human limbal 
epithelial cells (HLECs) in culture for the treatment of LSCD in 1997 (47). This is a relatively 
new technique, and no international or national guidance has yet been established. The basic 
technique includes harvesting HLECs from the contralateral healthy eye (or from a healthy 
area of an eye with partial LSCD) by performing a minimal limbal biopsy (2 x 2 mm2). In 
cases of bilateral total LSCD, one harvests allogenic HLECs from a living related donor or 
from fresh cadaveric tissue. The limbal biopsy is assumed to contain a population of LESCs, 
which are isolated and grown in a laboratory to produce a sheet of cultured limbal epithelial 
cells. This sheet will then be transplanted onto the cornea of the eye with the LSCD, after 
removal of the abnormal epithelium and the limbus. This may be combined with or followed 
by keratoplasty.  
 From the beginning, most studies report that the expansion of the cells require the use 
of non-human animal cells and products for co-culture, such as a mouse 3T3 fibroblast layer, 
fetal calf serum (FCS) in the growth medium in addition to various hormones and growth 
factors, including recombinant growth factor expressed in bacteria and Cholera Toxin. This 
technique creates two problems: The patient may require systemic immunosuppression, as the 
transplant would be a potential xenograft. The other more major concern is the potential of 
interspecies pathogen transfer from animal-derived products to humans when transplanting 
the graft – a concern that will be further augmented regarding the need for 
immunosuppression with this technique. To this day, it has been reported successful culture of 
LESCs on extracellular matrix components including collagen IV coated shields, laminin and 
fibronectin, human limbal fibroblasts, and human amniotic membrane (HAM).  
As pointed out by Shahdadfar et al in 2012 (54), the ideal method for establishing 
tissue equivalents for transplantation should include two features: 1) be approved and safe 
with respect to disease transmission, and 2) be able to recapitulate the tissue of origin after 
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integration, which for the corneal epithelium should include both LESCs with ability of self-
renewal and targeted differentiation, as well as differentiated epithelial cells to be able to 
protect the ocular surface.     
Of note, a few studies have reported transplantation of ex vivo cultured autologous 
oral mucosal epithelial cells to treat LSCD, as reviewed by Shortt AJ et al (46).  
 
5.1.2 Donor screening 
Ex vivo culture of HLECs carries a risk of transferring bacteria, viruses, and prions, both to 
the patient receiving the graft and to the laboratory staff performing the procedure of 
culturing. Therefore, screening of tissue donors and the risk of cross-contamination of 
cultures must be taken into consideration. Screening should include at least HIV, hepatitis B 
and C, syphilis, HTLV (human T lymphotrophic virus), and prion-related diseases (46). 
Screening can be performed by a questionnaire assessment or by serological testing. Whether 
or not screening was done, as well as the chosen method of screening, vary between different 
studies. Many studies do not report anything about screening, which may suggest that 
screening was not done, but lack of reporting is not conclusive of that (46).  
 
5.1.3 Culture systems 
There are two different types of culture systems. First, we have the “explant culture system”, 
where a small limbal biopsy is placed directly on an amniotic membrane and the limbal 
epithelial cells then migrate out of the biopsy and proliferate to form an epithelial sheet. In 
this method, the amniotic membrane acts both as a substrate and as a carrier for the cultured 
cells. It functions as a surrogate environmental stem cell niche. Usually, the amniotic 
epithelial cells are killed by the process of cryopreservation, and are then removed by 
enzymatic digestion, chemical treatment, or physical scraping of the membrane prior to use. 
After this, the limbal biopsy is placed directly onto the basement membrane surface of the 
amniotic membrane and will then adhere to it. Once attached, the biopsy and amniotic 
membrane are submerged in culture medium, which contains nutrients and mitogens to 
stimulate limbal epithelial cells to proliferate and migrate out of the biopsy and cover the 
amniotic membrane. This process usually occurs over 14-28 days. As reviewed by Shortt et 
al. (46), some studies report the use of an additional process termed airlifting. This requires 
the level of culture medium in the dish to be lowered to the level of the surface of the 
epithelium, which promotes stratification and differentiation of the epithelium.  
 
 
Figure 2. The explant culture system (46) 
This method employs amniotic membrane, which acts both as a substrate and a carrier for the cultured cells. The 
limbal biopsy is placed on the basement membrane surface of the amniotic membrane and allows to attach. Once 
attached, the biopsy and amniotic membrane are submerged in culture medium. HLECs migrate out of the 
biopsy and cover the surface of the amniotic membrane over 14 to 28 days. 
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A variant of the explant culture system is the “3T3 explant co-culture system” (46). 
An additional feeder layer of growth-arrested 3T3 fibroblasts is used in the bottom of the cell 
culture well. These cells are primitive cells with a high proliferative capacity that are isolated 
from embryonic mice. Growth arrest by irradiation or by treatment with mitomycin C prior to 
use stimulates the production of growth factors and matrix constituents that promote epithelial 
growth. Both the growth arrested 3T3 fibroblasts and the amniotic membrane inhibit the 
differentiation of corneal epithelial cells in vitro. This allows the expansion of the assumed 
LESC population. However, there is a potential risk of transplanting xenogenic tissue, in 
terms of infection, rejection or microchimerism (48). In order to reduce potential risks, some 
report the use of only clinical grade tissue, others only use of 3T3 cells at the beginning of 
culture before plating onto a secondary substrate (25,48).  
 
 
Figure 3. The explant co-culture system (46).  
This is a variation of the explant culture system in figure 2. This method uses an additional feeder layer of 
growth-arrested 3T3 fibroblasts in the bottom of the cell culture well. 
 
Secondly, we have the “suspension culture system”, in which HLECs are first released 
from the limbal biopsy after treatment with the enzymes dispase, which digests basement 
membrane collagen and separates clumps of HLECs into a suspension of single cells. A 
suspension of individual cells is then seeded onto an amniotic membrane or a plastic tissue 
culture dish that contains a layer of growth-arrested 3T3 feeder cells. Culture medium is then 
added, and the cells are incubated for 14 to 21 days. When the cells are confluent and have 
formed a sheet, a carrier substrate is used to transfer the cells to the eye. The carrier substrate 
may be fibrin gel, a contact lens, paraffin gauze or collagen shields. When an amniotic 
membrane is seeded with the suspension of single limbal epithelial cells, a layer of growth 
arrested 3T3-fibroblasts are added in the bottom of the dish as co-culture and the amnion 
itself serves as the carrier.  
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Figure 4. The suspension culture system (46).  
This method employs the enzyme dispase, which digests basement membrane collagen and separates epithelial 
cells from the stroma, and trypsin, which separates clumps of limbal epithelial cells into a suspension of single 
cells. This suspension is then seeded either onto amniotic membrane (left) or onto a plastic tissue culture dish 
that contains a feeder layer of growth arrested 3T3 fibroblasts (right). Culture medium is added and the cells 
incubated for 14 to 21 days. When confluent the epithelial sheet is transferred to the ocular surface using either a 
contact lenses, paraffin gauze, collagen shields, or fibrin gel. 
 
Although laboratory studies suggest that the suspension culture system is more efficient as a 
method of isolating LESCs for culture, there is no evidence of superiority supporting either 
system in terms of clinical outcome (46).  
Another variable is whether one positions the limbal explants with the epithelial or the 
stromal side down. Raeder et al’s study from 2007, suggests that when the limbal explants are 
positioned epithelial side down, it may give rise to a cultured epithelium with higher 
expression of the stem cell markers p63 and ΔNp63α (49). 
 
5.1.4 Carriers  
The LESCs are expanded to generate an epithelial sheet on transplantable carriers, such as 
amniotic membranes, fibrin gels and temperature-responsive polymers. The use of fibrin 
requires 3T3-feeder cells, which is an animal-derived product. HAM is generally accepted as 
non-immunogenic, and hence has some immunosuppressive as well as biodegradable 
properties during transplantation. Counter arguments for its use include its thickness, its 
variable transparency and the fact that it is a biological substrate, making it impossible to 
standardise. Human placenta is obtained shortly after an elective caesarean section delivery 
from an individual screened for HIV, hepatitis, and syphilis (43).  
The method of amniotic membrane preparation is a variable of importance as it may 
affect clinical outcomes. The amniotic membrane can be intact (non-decellularized), 
decellularized or partly decellularized. Koizumi et al compared intact with decellularized 
amniotic membrane for culture of LESCs (50). They found that the decellularized amniotic 
membrane supported the growth of well-stratified and differentiated limbal cells, whereas the 
intact amnion limbal cells failed to stratify and only formed a monolayer of cells in some 
places. The limbal cells cultivated on a decellularized amnion were well attached to the 
amniotic stroma and morphologically superior to limbal epithelial cells cultivated on an intact 
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amnion. The authors concluded that a decellularized amnion is superior for the purposes of 
transplantation of differentiated limbal epithelial sheets. Another finding was that the cells 
cultured on the decellularized amnion were more differentiated than those cultured on an 
intact amnion. This was also observed by Grueterich et al (51), who demonstrated that the 
intact amnion is superior to the decellularized amnion in terms of keeping the limbal stem cell 
phenotype ex vivo as well as after transplantation in an animal model. In 2008, Shortt AJ et 
al. (52), described the use of a cryopreserved amniotic membrane only partially 
decellularized, as a culture substrate in their study. This was performed by washing overnight 
in 50 mmol of ethylenediaminetetraacetic acid followed by gentle scraping, resulting in 
removal of 30-50 % of the amniotic epithelial cells.  
 
5.1.5 Culture medium 
The composition of the culture medium is essential for the culture of limbal epithelial cells; 
and fetal calf serum (FCS), various hormones and growth factors have been included in most 
culture methods for the treatment of LSCD to this day (46). Serum provides factors that are 
missing from the tissue culture media, including factors that promote cell growth and 
adhesion (53). FCS has been used extensively in epithelial culture systems; however, this 
induces the risk of prion diseases. Human autologous serum (HAS) has become an alternative 
to FCS in culturing of limbal epithelial cells. HAS is made from donated blood from the same 
patient who will receive the graft. The main drawbacks include the screening process, the fact 
that the patient has to be medically suitable to donate blood and the cost. As a blood product, 
there is also a risk that the serum may carry an unknown infection.  
As reviewed by Shahdadfar A et al. in 2012 (54), the use of HAS for expansion of 
HLECs was first introduced and proved its efficacy in a setting where the cells were expanded 
on plastic contact lenses (55), and a mixture of complex medium and human serum has been 
shown to support expansion of HLECs.  
In 2009, Kolli S. et al (41) published a study reporting successful ex vivo expansion of 
HLECs using HAS as a replacement for FCS in culture medium combined with HAM as 
matrix. First, they managed to successfully culture HLECs on HAM as both explant and 
single-cell suspension cultures in FCS containing media. Their findings indicated that the 
limbal explant culture covered outgrowth covered the amniotic membrane much earlier than 
the suspension cultures, but both culture systems showed successful growth. Further, they 
investigated whether the ex vivo single-cell expansion of limbal epithelial cultures could be 
achieved on 3T3 feeders using medium supplemented with HAS as a replacement for FCS. 
There were no statistically significant difference between p63 expression or the colony-
forming efficiency of the limbal epithelial cells from the cultures established using either FCS 
or HAS. For clinical purposes, Kolli S. et al. used the explant culture system on HAM with a 
modified epithelial growth medium supplemented with HAS instead of FCS. There were no 
statistically significant differences between the two culture system methods regarding 
morphological observations, flow cytometry analysis for expression of p63 and colony-
forming efficiency. The HAS-containing cultures had significantly larger outgrowths, 
corroborated by higher cell counts in the HAS ex vivo expanded cultures. The conclusion of 
this case study was successful and long-term (at least 2 years) reversal of LSCD using both 
objective and subjective measurements for all the eight participating patients after 
transplantation of ex vivo expanded autologous limbal epithelium using an explant technique 
on intact HAM cultured with a non-human animal cell free, GMP compliant system.  
In 2012, Shahdadfar A et al (54), reported successful ex vivo expansion of autologous 
HLECs on HAM using a culture medium with HAS as single supplement – the culture 
medium was free of both animal derived products and other growth supplements such as 
exogenous growth factors, hormones and cholera toxin. This was compared with a complex 
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medium including FCS. Rama et al (25) has shown that even though the formation of 
holoclones is the “gold standard” to identify LESCs, the percentage of p63 bright cells is 
indicative of the clinical outcome after transplantation to patients with LSCD. This 
transcription factor may therefore be used to detect viable LESCs prior to transplantation. In 
Shahdadfar and coworkers’ study, cultivation with HAS increased the expression, both on the 
mRNA level and on the protein level, of p63 in the expanded HLECs compared to cultures 
with a complex medium, but there were no statistical differences between the numbers of 
p63α positive cells. They also reported that their microarray data indicated a 5 times 
downregulation of ALDH1A1 in HAS culture compared to the complex medium, and that it is 
known that ALDH(dim) human epithelial cells expresses significantly higher levels of ΔNp63 
and ABCG2 in addition to having a greater colony forming efficiency when compared to 
ALDH(bright) cells. In conclusion, they report that these data indicate that a culture medium 
with HAS as single supplement is an equivalent replacement for the commonly used complex 
medium for ex vivo expansion and transplantation of human limbal epithelial cells on HAM. 
Further, markers of corneal epithelial cells including cytokeratin 3 and 12, were more or 
similarly expressed in the HAS culture compared with the complex medium. This indicated 
that HAS is not inferior in the ability to initiate proper terminal differentiation of the cell 
types needed to protect the ocular surface. This is in agreement with Nakamura et al’s study 
from 2006 (56), where they evaluated the use of HAS versus FCS in ex vivo cultivation of 
human limbal epithelial cells in a medium also containing several hormones and growth 
factors, and they concluded that medium with HAS and FCS were equivalent.  
 
5.2 Surgical transplantation of ex vivo expanded LESC grafts 
As reviewed by Shortt et al in 2007 (46), all studies reported a similar technique for 
transplanting ex vivo cultured HLECs. A 360° peritomy (peritectomy) was performed to start 
with, followed by dissection of the fibrovascular pannus and ingrowing conjunctival tissue 
from the cornea and limbus. Cautery, with or without topical 10 % phenylephrine, was used to 
achieve hemostasis. Some studies describe application of mitomycin C to the subconjunctival 
space followed by vigorous irrigation in an attempt to prevent conjunctival ingrowth in the 
postoperative period. The ex vivo cultured graft was then placed onto the prepared corneal 
surface and limbus. To prevent desiccation of the cultured cells after removal from the 
transport medium, sodium hyaluronate was used. In the cases where cells were grown on an 
amniotic membrane or a fibrin membrane, the graft was placed directly on the corneal stroma 
with the cultured cells facing outwards into the tear film. The graft was then secured by 
suturing with 10/0 vicryl or nylon. When the epithelial sheet was transplanted without a 
carrier, the basal aspect of the sheet was placed directly onto the corneal stroma and suturing 
was not necessary. Another technique to treat partial LSCD, described by Tsai et al, was to 
replace only the sectorial areas presenting with LSCD with grafts that were cut to the exact 
size of the diseased areas (57).  
Nakamura et al have reported successful removal of the amniotic membrane and 
regrafting using the same procedure as described above in the event of a failed graft, which 
was defined as recurrence of conjunctival ingrowth and the signs of corneal 
conjunctivalization (58).  
 
5.3 Protection of transplanted cells 
There are different methods to protect the cells after transplantation, including the use of a 
bandage contact lens, tarsorrhaphy, tape closure of the lids and placement of an extra human 
amniotic membrane sutured over the transplant (44,46). When a contact lens is used for 
mechanical protection, it is placed over the graft at the end of surgery and kept in place for 1 
week to 3 months. The studies that report protection by an amniotic membrane onlay, 
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describe that it is sutured to the limbus and that it is later sloughed or dissolved over the next 
10 to 21 days. Some studies report no use of any method of protection.  
 
5.4 Post-operative medication 
The basic principles of the postoperative management are immediate control of inflammation, 
prophylaxis against infection, mechanical protection of the graft, and prevention of allograft 
rejection. No international standards have been established yet, and different studies report 
different regimes. In all studies reviewed by Shortt et al in 2007, a topical unpreserved steroid 
and a broad spectrum antibiotic (ofloxacin or chloramphenicol) were administered four times 
a day starting immediately after transplantation and continued for 1 to 3 months. It has been 
reported that autologous serum drops probably promote epithelial healing (43). The use of 
systemic immune suppression is reported in most studies where patients received allogenic 
grafts. Some studies also used immune suppression for patients who received autografts (59). 
All studies, reviewed by Baylis et al. in 2011 (44), with immune suppression regimes, used 
cyclosporine. Some studies combined that with cyclophosphamide. One patient received 
mycophenolate motefil alone. A small number of patients did not receive any immune 
suppression at all. Another variable is the dose of the immune suppression therapy, and the 
optimum dose has not been established. Only some of the studies reported the duration of 
received immune suppression, varying from 1 to 12 months. Due to the lack of evidence of 
detectable donor DNA on the corneal surface 9 months after surgery, Daya et al. (60) have 
argued that systemic immune suppression is not necessary beyond that period of time.  
In 2004, Cooper et al. (61) described the histological and electron microscopic 
analysis of three failed ex vivo cultured grafts of limbal epithelial cells that had been 
removed. They observed destruction of HLECs, the presence of inflammatory cells and 
ingrowth of conjunctival epithelial cells beneath remaining islands of transplanted limbal 
epithelium. This supports the use of immune suppression at least during the first 6 months 
after treatment, as the findings suggest that transplanted allogenic cells are the targets of an 
immune response (61).  
 
5.5 Assessment of outcomes 
 
5.5.1 Objective clinical assessment of outcomes 
In the studies reviewed by Baylis et al. in 2011 (44), including 28 case reports and series 
published 1997-2010, various methods of objective scoring of LSCD were reported. 
Baradaran-Rafii et al. (62), used a scoring system from 0-4 whereby two examiners used slit-
lamp examination and clinical photographs to grade epithelial transparency and superficial 
vascularisation. Other studies reported similar techniques. Only one study reported confocal 
microscopy to assess outcome. Corneal impression cytology was described in 10 studies to 
confirm the diagnosis of LSCD pre-operatively, but only 7 studies used it as part of follow-up 
after the transplantation. 9 studies used corneal tissue, removed at the time of the subsequent 
corneal transplantation, for analysis by histological and immunohistochemical techniques to 
look for presence of a normal corneal phenotype. 
Of note, Daya et al (60) used polymerase chain reaction (PCR) genotyping to 
investigate the origin of the cells on the ocular surface post-operatively in the purpose of 
looking for direct evidence of cell survival. Their findings suggest that the epithelium on the 
ocular surface on the majority of the patients was of a host genotype and that donor cells may 
persist for 7 to 9 months post-operatively, but are replaced by host cells thereafter. If this is 
true, it may indicate that transplantation of ex vivo cultured limbal epithelial cell grafts is 
successful because it serves as a niche for the regeneration of the host stem cell population 
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and not because it provides a population of LESCs that continue to function over a prolonged 
time period.  
 
5.5.2 Subjective clinical assessment of outcomes 
Subjective assessments of outcomes were only included in 10 out of the 28 studies in the 
review. Only 2 studies used formal assessments. These included the global symptom score, 
the facial expression analogue (55) and visual analogue scores for pain and vision impairment 
(41). Quality of life assessment is also an important measure of outcome for two main 
reasons. Firstly, it is important to maintain a holistic view for patients for any condition. 
Secondly, there are limited resources in most healthcare systems; thereby it is essential to 
consider quality of life measures to justify the resource allocation.  
 
5.6 Success rates 
 
5.6.1 Overall success rates 
In Baylis et al.’s review from 2011 (44), the overall success rate was 76 % (77 % for 
autografts, 73 % for allografts). This number is based on restoration of the corneal epithelium 
clinically. 51 % also had an improvement of 2 or more lines Snellen visual acuity. The 
comparing of studies in the review was difficult due to variable patient numbers in each study 
and other variable factors influencing the outcome such as underlying diagnosis, source of 
material, culture method, surgery, post-operative care and length of follow-up. Another 
problematic factor is that what was considered a successful outcome varied between the 
studies. Still, there seems to be fairly consistent success rates. This is consistent with the 
previous outcome review from 2007 by Shortt et al. (46). Of note, it is predicted that there are 
a number of patients whose outcomes are not published, something that is important to keep 
in mind.  
 
5.6.2 Success rates by cause 
According to the pooled results reviewed by Baylis et al in 2011 (44), the success rate for 
chemical/thermal burns is 75 %, congenital causes is 60 %, inflammatory disease is 86 %, and 
other causes 80 %.  
 
5.6.3 Success rate by method of culture 
It is very difficult to compare which culture methods and study protocols that are most 
successful in terms of clinical outcome due to all the other variables. As reviewed by Baylis et 
al (44); Shimazaki et al report (63) a 50 % success rate (8 out of 16) using the explant culture 
technique, and a 73 % success rate (8 out of 11) using the suspension culture technique. 
However, this study includes few patients and the difference may be explained by different 
aetiologies of the LSCD treated and also the fact that more patients in the suspension group 
received autologous grafts. In 2006, Nakamura et al (56) report performing 2 explant cultures 
using autologous tissue and 6 suspension cultures using allogenic tissue. The results were 100 
% success with both methods, but the study does not favour any method over the other.  
Rama et al. (25) describes that a minimum of approximately 3000 stem cells, detected 
as p63-bright holoclone-forming cells, was required to achieve clinical success. Analyses of 
their findings suggest that the outcomes differed significantly depending on whether the 
transplanted cultures contained more than 3 % p63-bright holoclone-forming stem cells or 3 
% or less – with success rates of 78 % with the larger number of stem cells and 11 % with the 
smaller number.  
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5.6.4 Success rate based on improvement in vision 
A success rate based on improvement in vision is difficult to make due to different 
measurement methods of this parameter. Baylis et al identified the number of eyes improving 
by more than or equal to two lines of Snellen acuity from the studies where this was reported 
(44). To be able to make a comparison, Baylis et al reported that in order to achieve an 
improvement of two lines of Snellen acuity, the final vision level had to be at least 20/200, 
and the number of Snellen lines improved was counted. By this definition, 51 % of eyes 
receiving cultured limbal epithelial grafts had more than or equal to two lines of visual 
improvement. Of note, in the case of partial LSCD, visual acuity may be reasonable from the 
start and even success may not give improvement of two lines by Snellen acuity score. Few 
studies report systematically recording of stromal scarring. If stromal scarring is present, the 
patient may report success in term of pain relief, but improvement of vision may be lacking. 
In some studies this was only possible to presume by the number that had simultaneously or 
subsequent corneal transplantation. Baylis et al suggest that improvement of vision ideally 
should be recorded using LogMAR acuity.  
 
5.7 Complications 
Complications following transplantation of the grafts include inflammation, bleeding, ocular 
perforation, infection, glaucoma, and complications related to cyclosporin. Some studies 
report “no complications”. The classification and reporting of complications vary widely 
between the studies (44).  
 
5.8 Follow-up 
In the review by Baylis et al (44), nearly all patients had more than 6 months of follow-up. 
The average time of follow-up was 24 months. Complete renewal of the corneal epithelium is 
estimated to take 9-12 months. Nearly all failures occur within the first 2 years following 
transplantation. In conclusion, the optimal length of follow-up should ideally be at least 24 
months.   
 
5.9 Challenges due to multiple variables 
In general, a problem with studies investigating the outcome of limbal epithelial cell 
expansion and transplantation is, as mentioned, that there is no established guidance for the 
technique, nor are there any standardization regarding criteria for the patients being included 
in the studies, such as criteria used to diagnose LSCD, total versus partial LSCD, unilateral 
versus bilateral cases, the cause of LSCD (acquired and congenital), the age and gender of the 
patients and comorbid conditions. Other variables in the studies are the source of initial tissue 
(allo- and autografts), methods of ex vivo expansion (explant or single cell; HAM or 3T3 
fibroblast co-culture or both), composition of the culture medium, the surgical management 
(method of superficial keratectomy, the use of a second HAM as a bandage, contact lens 
protection, or both), postoperative management (use of HAS or not, immunosuppression 
regimes), time period of follow up, and definition of a successful outcome (41). This makes it 
hard to compare the results of different studies and to conclude on which methods are the 
best.  
 
5.10 Good manufacturing practice and regulations 
Defined by the World Health Organization; Good Manufacturing Practices (GMP) is the 
aspect of quality assurance that ensures that medicinal products are consistently produced and 
controlled to the quality standards appropriate to their intended use and as required by the 
product specification. GMP defines quality measures for both production and quality control 
and defines general measures to ensure that processes necessary for production and testing are 
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clearly defined, validated, reviewed, and documented, and that the personnel, premises and 
materials are suitable for the production of pharmaceuticals and biologicals. GMP also has 
legal components. Specific GMP requirements apply to distinct classes of products, such as 
biological medicinal products. 
Cultured limbal epithelial cells for transplantation are classified as investigational 
medical products. In the UK, they are regulated by the Medicine and Healthcare Products 
Regulatory Agency (MHRA) in compliance with Tissues and Cells Directive 2004/23/EC, 
article 1 of Directive 2001/83/EC, article 2 of Regulations No. 1394/2007, amending 
Directive 2001/83/EC and Regulations (EC) No. 726/2004 (44). The European Medicines 
Agency and the US Food and Drug Administration both have close links to the MHRA. In 
Europe as well as all other countries worldwide, the production of cultured human limbal 
epithelium must be carried out under good medical practice in a specifically licenced 
laboratory. To obtain a licence, the MHRA (from 2007) require that the entire production 
process, including raw materials, manufacturing, supply and storage, must be assessed and 
approved. Also, there must be stringent ongoing quality control and inspections. These 
regulations have a huge impact on the research because the process of obtaining a licence 
requires a huge input of validation, time and funding. As a consequence, the cost of treating 
each patient increases.    
 
6. LIMBAL STEM CELL THERAPY AT OSLO UNIVERSITY HOSPITAL 
ULLEVÅL 
 
At present, the Department of Ophthalmology at Oslo University Hospital is the only centre 
in Scandinavia offering patients with LSCD treatment with transplantation of ex vivo 
expanded autologous HLECs. The department currently uses the explant culture system with 
HAM as the carrier and a culture medium with HAS as single supplement. A recent study 





It is widely accepted today that stem cells in the adult corneal epithelium is located to the 
limbus, as first proposed by Davanger and Evensen in 1971. No specific marker of LESCs has 
been identified, yet many have been suggested, including ΔNp63α, ABCG2, vimentin and 
notch 1. Negative markers include amongst others the differentiation markers Ck3 and Ck12. 
The lack of an identified specific marker elucidates the need for establishment of more exact 
molecular markers of LESCs. 
LSCD may result from a variety of aetiologies, such as chemical and thermal injuries, 
keratitis and aniridia, and represents an important cause of loss of vision and blindness 
worldwide. There is an ongoing discussion about the definition of this condition and a 
diagnosis with clear criteria has not been established for LSCD. The treatment options vary 
depending on the presentation of the LSCD – partial versus total and unilateral versus 
bilateral. In the case of partial LSCD when the central cornea and the visual axis are not 
affected, conservative management is indicated, including non-preserved lubrication, bandage 
contact lenses, and autologous serum eye drops. If there is involvement of the central cornea 
in partial LSCD, surgical management is indicated. The management includes mechanical 
debridement of conjunctival epithelium from the corneal surface and/or amniotic membrane 
transplantation. When total LSCD is present, surgical management with replacement of the 
damaged or absent limbal stem cells is currently the treatment of choice. The transplants can 
either be large whole tissue limbal epithelial grafts, or ex vivo expanded limbal epithelial 
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grafts from small biopsies of limbal epithelium. The expanded HLECs can be autologous 
(autografts) or allogenic (allografts), the latter when the HLECs are obtained from a living 
relative donor or from cadaveric tissue. There are two major advantages in using ex vivo 
expanded autografts; only a small amount of tissue is required, and thereby the LESC 
population of the donor eye is less likely to be damaged. The second advantage is that the 
donor tissue is autologous and thereby no systemic immunosuppression is required. In 
addition, autologous oral mucosa grafts have been used to treat LSCD.   
Pellegrini and co-workers were the first to describe ex vivo expansion of HLECs in 
culture for the treatment of LSCD in 1997. Still, ex vivo expansion of HLECs is a relatively 
new technique, and no international or national guidance has been established. This has 
resulted in several studies seeking to investigate this technique, but these studies are hard to 
compare due to different variables, such as the criteria used to diagnose LSCD, total versus 
partial LSCD, unilateral versus bilateral cases, the cause of LSCD (acquired and congenital), 
the age and gender of the patients included, presence of comorbid conditions, methods of ex 
vivo expansion, the source of initial tissue (allo- and autografts), composition of the culture 
medium, the surgical management, postoperative management, time period of follow up, and 
definition of a successful outcome. 
The composition of the culture medium is essential for the culture of limbal epithelial 
cells, and fetal calf serum, various hormones and growth factors have been included in most 
studies. Concern has been raised about the use of animal-derived products in the culture 
systems where LESCs are expanded, as this implies a possibility for interspecies pathogen 
transfer when transplanting the grafts, including prion diseases. This risk is further augmented 
due to the fact that immunosuppression is required. In the past years, researches have 
investigated options trying to exclude animal-derived products from the entire process. The 
use of HAM has been introduced and proved successful as a substitute for fibrin combined 
with feeder cells or other materials. FCS has successfully been replaced with HAS in the 
culture medium in some studies. A goal is to have a culture system free of animal-derived 
products throughout the entire process.  
So far, transplantation of these grafts has shown promising results as a way of treating 
LSCD with an overall success rate of 76 %. Although this number is based on studies with a 
wide range of differences, the success rates seem to be fairly consistent. Long-term follow-up 
is needed to investigate whether the outcomes are successful over a longer period of time as 
well, although the overall results seem convincing to this day. More research in this field is 
required to improve the established, but not yet standardised, techniques. Ideally an 
international guidance should be established for a culture method free of non-human derived 
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